期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 194, 期 6, 页码 954-969出版社
WILEY
DOI: 10.1111/bjh.17403
关键词
aplastic anaemia; eltrombopag; immunosuppressive therapy; anti‐ thymocyte globulin; cyclosporin; bone marrow failure
类别
The advances in the management of aplastic anaemia (AA) have been successful, with better understanding of the mechanisms underlying the reduction of hematopoietic stem cells (HSCs) and improvements in supportive care. Efforts to increase immunosuppression potency and stimulate HSCs have not achieved better outcomes, but the use of thrombopoietin receptor agonists (Tpo-RA) has been effective in stimulating early HSCs despite high endogenous Tpo levels.
The progress in aplastic anaemia (AA) management is one of success. Once an obscure entity resulting in death in most affected can now be successfully treated with either haematopoietic stem cell transplantation (HSCT) or immunosuppressive therapy (IST). The mechanisms that underly the diminution of haematopoietic stem cells (HSCs) are now better elucidated, and include genetics and immunological alterations. Advances in supportive care with better antimicrobials, safer blood products and iron chelation have greatly impacted AA outcomes. Working somewhat 'mysteriously', anti-thymocyte globulin (ATG) forms the base for both HSCT and IST protocols. Efforts to augment immunosuppression potency have not, unfortunately, led to better outcomes. Stimulating HSCs, an often-sought approach, has not been effective historically. The thrombopoietin receptor agonists (Tpo-RA) have been effective in stimulating early HSCs in AA despite the high endogenous Tpo levels. Dosing, timing and best combinations with Tpo-RAs are being defined to improve HSCs expansion in AA with minimal added toxicity. The more comprehensive access and advances in HSCT and IST protocols are likely to benefit AA patients worldwide. The focus of this review will be on the medical treatment advances in AA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据